Caas Capital Management LP Eli Lilly & CO Call Options Transaction History

Caas Capital Management LP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Oct 28, 2024	BUY	$772.14 - $960.02 $5.95 Million - $7.39 Million	7,700 New	7,700 $6.82 Million
Q3 2022 Nov 14, 2022	BUY	$296.48 - $337.87 $3.82 Million - $4.36 Million	12,900 New	12,900 $4.17 Million
Q1 2022 May 13, 2022	SELL	$234.69 - $291.66 $41.1 Million - $51 Million	-175,000 Reduced 87.5%	25,000 $7.16 Million
Q3 2021 Nov 15, 2021	BUY	$221.6 - $272.71 $36.9 Million - $45.5 Million	166,700 Added 500.6%	200,000 $46.2 Million
Q1 2021 May 17, 2021	BUY	$164.32 - $212.72 $5.23 Million - $6.76 Million	31,800 Added 2120.0%	33,300 $6.22 Million
Q3 2020 Nov 09, 2020	SELL	$146.22 - $169.13 $5.26 Million - $6.09 Million	-36,000 Reduced 96.0%	1,500 $222,000
Q2 2020 Aug 14, 2020	BUY	$136.42 - $164.18 $3.81 Million - $4.58 Million	27,900 Added 290.63%	37,500 $6.16 Million
Q1 2020 May 15, 2020	BUY	$119.05 - $147.35 $1.14 Million - $1.41 Million	9,600 New	9,600 $1.33 Million

4,003

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $716B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.